Microcap Research·Est. 2026
TSXV: IOT · Life Sciences Services / Laboratory Testing

Innovotech Inc.

Microcap Research rates Innovotech Inc. (TSXV: IOT) Hold with a 12-month price target of C$0.10, about 25% above the C$0.08 share price at publication on Aug 19, 2026. Market capitalisation at publication: C$4.36M.

Latest Rating
Hold
12-mo Target
C$0.10
Price at Publication
C$0.08
Implied Upside
+25%
Market Cap
C$4.36M

Coverage history 02 reports

01
Innovotech IOT-2026-08-Q2update Current
Q2 broke the thesis. Management confirmed the lost client program is permanent and that antimicrobial revenue is back at 2024 levels — reframing FY2025 as a peak, not a platform. Gross margin collapsed to 8.6% and cash fell 77% to C$374,671. The stock is 6% cheaper per share than at initiation but enterprise value is 29% higher. Downgrade to Hold, target C$0.10.
Life Sciences Services / Laboratory Testing
Hold
+25%
02
Innovotech IOT-2026-07 Superseded
A textbook microcap dislocation: a GMP-accredited lab-services business that doubled revenue to C$4.53M and earned a profit in 2025, now trading at ~0.73x EV/Revenue after a single client program ended and cratered Q1 2026 revenue 44%. With C$1.32M cash, a 3.28x current ratio, and GLP certification underway, the market is pricing a real stumble as if it were terminal.
Life Sciences Services / Laboratory Testing
Spec. Buy
112%

Innovotech Inc. (IOT) — key questions

What is Microcap Research's current rating on Innovotech Inc. (IOT)?

Microcap Research rates Innovotech Inc. (TSXV: IOT) Hold with a 12-month price target of C$0.10, about 25% above the C$0.08 share price at publication on Aug 19, 2026. Market capitalisation at publication: C$4.36M. This is the current call, published in the most recent of 2 Microcap Research reports on the company.

How many reports has Microcap Research published on Innovotech Inc. (IOT)?

2 reports, beginning in 2026. The most recent is dated Aug 19, 2026; the earlier report remains online as the published record, each marked superseded and linked to the report that replaced it.

Has Microcap Research's rating on Innovotech Inc. (IOT) changed?

Microcap Research initiated coverage of Innovotech Inc. (IOT) on Jul 2, 2026 at Spec. Buy, with a C$0.18 price target. Across 2 reports since then, on Aug 19, 2026 the rating moved from Spec. Buy to Hold at a C$0.10 target. The current call, from Aug 19, 2026, is Hold at C$0.10.

What does Innovotech Inc. (IOT) do?

Innovotech Inc. is a Life Sciences Services / Laboratory Testing company listed on the TSXV as TSXV: IOT. Innovotech operates ISO-certified and GMP-accredited laboratories serving medical-device, pharmaceutical, and industrial clients across Canada, the United States, and international markets. Following the January 2026 amalgamation, the business now reports as a single operating segment, but its revenue still spans several distinct service lines:

What are the main risks Microcap Research flags on Innovotech Inc. (IOT)?

As of the Aug 19, 2026 report — Liquidity (HIGH, materially escalated); Facility Purchase Commitment (HIGH, new); Dilution (HIGH, new); Revenue Base Reset (HIGH, was Customer Concentration); Gross Margin / Utilization (HIGH, escalated from MEDIUM); Keystone Underperformance (MEDIUM, new); Liquidity / Small-Cap Risk (HIGH, unchanged)